<DOC>
	<DOCNO>NCT01448915</DOCNO>
	<brief_summary>The principal goal research project evaluate extent HCV disease treatment coinfected IDUs . Research procedures focus determine liver disease prevalence grade disease within population . The investigator also evaluate behavioral reinforcement intervention increase rate treatment participation completion .</brief_summary>
	<brief_title>Management Hepatitis C HIV Infected Injection Drug Users ( IDUs )</brief_title>
	<detailed_description>The principal goal research project remain focused hepatitis C virus ( HCV ) infection HIV-infected injection drug user ( IDUs ) . The recent availability novel , non-invasive method measure HCV disease stage make possible test relationship HCV disease stage management coinfected IDUs adequate precision . The investigator apply innovative technology , elastography ( FibroScan® ) ask whether marked difference final disease outcome , end-stage liver disease ( ESLD ) , explain measure liver stiffness assess elastography ( FibroScan® ) . While advance non-invasive disease assessment critical HCV management , great challenge improve HCV treatment effectiveness coinfected person remain low rate treatment uptake adherence , even freely accessible . In response glaring disparity , investigator test potent behavioral reinforcement intervention improve management HCV disease adapt rigorously study contingent behavioral incentive program treatment coinfected IDUs . Hepatitis C Treatment Eligibility : To determine population prevalence significant liver disease coinfected IDUs use innovative , non-invasive methodology ( transient elastography , FibroScan® ) measure liver stiffness . Liver Disease Staging : To test hypothesis liver stiffness , assess novel , non-invasive methodology , predictive development ESLD , define hepatic decompensation , hepatocellular cancer , liver-related death , coinfected IDUs . Hepatitis C Treatment Incentives : To test hypothesis contingent behavioral reinforcement intervention effectively increase proportion coinfected IDUs initiate , attend , complete HCV treatment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>History substance abuse Reactive HCV antibody Reactive HIV antibody For treatment arm , HCV treatment eligible define absence absolute contraindication HCV treatment : HCV RNA detect PCR Pregnant willing use birth control Life expectancy &lt; 2 year Severe depression suicidal ideation Allergy interferon and/or ribavirin Severe hematologic abnormality Renal insufficiency Women may undergo FibroScan pregnant Persons implant cardiac device may undergo FibroScan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Human immunodeficiency virus</keyword>
	<keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
	<keyword>AIDS virus</keyword>
	<keyword>Immunodeficiency Virus , Human</keyword>
	<keyword>Virus , Human Immunodeficiency</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C , chronic</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Hepatitis C antibody</keyword>
	<keyword>Hepatitis C antigen</keyword>
</DOC>